| Market revenue in 2024 | USD 3,763.4 million |
| Market revenue in 2030 | USD 6,503.5 million |
| Growth rate | 9.7% (CAGR from 2025 to 2030) |
| Largest segment | Formulation development |
| Fastest growing segment | Formulation Development |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preformulation, Formulation Development |
| Key market players worldwide | SGS, Intertek Group PLC, Recipharm, Lonza Group Ltd, Charles River Laboratories International Inc, Eurofins Scientific SE, Element Solutions Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Catalent Inc |
There are several reasons why India has become one of the most profitable markets for outsourcing drug formulation development services, including the availability of industry expertise, WHO-cGMPcompliant facilities, and affordable drug discovery services.
The initiatives of the government of India and investments in R&D programs further boosted the growth of the formulation development outsourcing market in the country. The Pharma Letter said that India's operational expenses were 40% lower than those of other countries, providing considerable financial advantages for international corporations.
India has been one of the most sought-after locations for conducting research operations as a result of the growth in government financing for R&D to speed up new product development. In the coming years, it is anticipated that these factors, along with India's favorable regulatory framework and a large pool of talented scientists & researchers, will encourage market expansion in the country.
Publish Date: -
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Intertek Group PLC | View profile | 44,000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | www.intertek.com |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | www.recipharm.com |
| Element Solutions Inc | View profile | 5,300 | 500 East Broward Boulevard, Suite 1860, Fort Lauderdale, FL, United States, 33394 | www.elementsolutionsinc.com |
| SGS | View profile | 10001+ | Geneva, Geneve, Switzerland, Europe | www.sgs.com/ |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Formulation Development Outsourcing Market Outlook will help companies and investors design strategic landscapes.
Formulation Development was the largest segment with a revenue share of 84.48% in 2024.
Horizon Databook has segmented the India formulation development outsourcing market based on preformulation, formulation development covering the revenue growth of each sub-segment from 2018 to 2030.
There are several reasons why India has become one of the most profitable markets for outsourcing drug formulation development services, including the availability of industry expertise, WHO-cGMPcompliant facilities, and affordable drug discovery services.
The initiatives of the government of India and investments in R&D programs further boosted the growth of the formulation development outsourcing market in the country. The Pharma Letter said that India's operational expenses were 40% lower than those of other countries, providing considerable financial advantages for international corporations.
India has been one of the most sought-after locations for conducting research operations as a result of the growth in government financing for R&D to speed up new product development. In the coming years, it is anticipated that these factors, along with India's favorable regulatory framework and a large pool of talented scientists & researchers, will encourage market expansion in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the India Formulation Development Outsourcing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into India Formulation Development Outsourcing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
